Outlook Therapeutics (OTLK) Non-Current Assets (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Non-Current Assets data on file, last reported at $987695.0 in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $987695.0, down 22.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 17.09% YoY), and the FY2025 annual result was $1.2 million, down 15.06% from the prior year.
• Non-Current Assets declined to $987695.0 in Q1 2026 per OTLK's latest filing, from $1.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $1.5 million in Q2 2024 and troughed at $971901.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets retreated 22.71% in 2022, then surged 33.01% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $1.0 million in 2022, then rose by 27.98% to $1.3 million in 2023, then increased by 3.31% to $1.3 million in 2024, then slipped by 19.92% to $1.1 million in 2025, then fell by 7.87% to $987695.0 in 2026.
• Business Quant data shows OTLK's Non-Current Assets at $987695.0 in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.